A new strategy to reduce the side effects suffered by patients undergoing treatment for head and neck cancers now has the support of the National Institutes of Health.
Nucleix : Establishes Collaborative Research and License Agreement with MD Anderson to Develop Methylation Assays to Assess Lung Cancer Patients
06/03/2021 | 08:10am EDT
Send by mail :
Message :
Agreement to build upon research and technical expertise in characterizing methylation patterns in lung cancer
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has entered into a collaborative research and license agreement with The University of Texas MD Anderson Cancer Center to evaluate and develop methylation assays focused on lung cancer, using Nucleix’s highly sensitive EpiCheck® platform.
The collaboration will focus initially on evaluating methylation markers believed to be important for the characterization of lung cancer subtypes. Selected markers will be evaluated using EpiCheck – Nucleix’s proprietary platform, which can be run using both PCR and next-generation sequencing technologies, and has shown best-in-class an
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders
Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders
Data suggest abscopal effect in some patients (i.e., reduction in non-injected non-irradiated lesions)
To date, the overall adverse event profile for the 16 injected patients has not differed from what is expected with radiotherapy or anti-PD-1 agents (head and neck cancer and non-small cell lung cancer primary tumors)
Acumen Research and Consulting, a global provider of market research studies, has recently published a report titled “Brain Metastasis Therapeutic Market –.